Human Genome Epidemiology Literature Finder
Records 1 - 13 (of 13 Records) |
Query Trace: Nausea and TP53[original query] |
---|
Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics 2010 Oct 11 (10): 1377-87. Sakano Shigeru, Hinoda Yuji, Sasaki Miwa, Wada Takashi, Matsumoto Hiroaki, Eguchi Satoshi, Shinohara Asano, Kawai Yoshihisa, Hara Tomohiko, Nagao Kazuhiro, Hara Takahiko, Naito Katsusuke, Matsuyama Hideya |
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. European journal of cancer (Oxford, England : 1990) 2017 Mar 76 144-151. de Jonge Maja, de Weger Vincent A, Dickson Mark A, Langenberg Marlies, Le Cesne Axel, Wagner Andrew J, Hsu Karl, Zheng Wei, Macé Sandrine, Tuffal Gilles, Thomas Koruth, Schellens Jan H |
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 2018 Feb 9 (10): 9114-9136. Tecza Karolina, Pamula-Pilat Jolanta, Lanuszewska Joanna, Butkiewicz Dorota, Grzybowska E |
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299. Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo |
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. British journal of cancer 2018 12 120 (3): 286-293. de Weger Vincent A, de Jonge Maja, Langenberg Marlies H G, Schellens Jan H M, Lolkema Martijn, Varga Andrea, Demers Brigitte, Thomas Koruth, Hsu Karl, Tuffal Gilles, Goodstal Samantha, Macé Sandrine, Deutsch Er |
[Cerebrospinal fluid TP53 gene mutation in patients with lung cancer associated meningitis and its clinical implications]. Zhonghua yi xue za zhi 2020 4 100 (11): 823-827. Li X Q, Huang M, Chen X X, Zou Y L, Yan L T, Zhao H, He J Y, Bu |
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational new drugs 2020 2 38 (5): 1430-1441. Uy Geoffrey L, Assouline Sarit, Young Anne-Marie, Blotner Steven, Higgins Brian, Chen Lin-Chi, Yee Kar |
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific reports 2020 2 10 (1): 3080. Wang Yudong, Janku Filip, Piha-Paul Sarina, Hess Kenneth, Broaddus Russell, Liu Lidong, Shi Naiyi, Overman Michael, Kopetz Scott, Subbiah Vivek, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James, Fu Siqi |
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2021 12 163 19-26. Plummer Ruth, Dean Emma, Arkenau Hendrik-Tobias, Redfern Charles, Spira Alexander I, Melear Jason M, Chung Ki Y, Ferrer-Playan Jordi, Goddemeier Thomas, Locatelli Giuseppe, Dong Jennifer, Fleuranceau-Morel Patricia, Diaz-Padilla Ivan, Shapiro Geoffrey |
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. European journal of cancer (Oxford, England : 1990) 2022 Sep 173 238-249. Ma Yuxiang, Zhao Hongyun, Xue Jinhui, Liu Li, Yang Nong, Zhang Yang, Yang Haiyan, Hong Shaodong, Xiong Yi, Zhang Zhonghan, Zeng Liang, Pan Hui, Zhou Chunhua, Zhang Yongchang, Wang Xunqiang, Han Xi, Wan Xiaojing, Shao Yang, Liu Jingwen, Yang Yunpeng, Huang Yan, Zhao Yuanyuan, Fang Wenfeng, Li Su, Zhang |
Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer. Dose-response : a publication of International Hormesis Society 0 20 (2): 15593258221111666. Spasic Jelena, Cavic Milena, Stanic Nemanja, Zaric Bojan, Kovacevic Tomi, Radosavljevic Davorin, Nagorni-Obradovic Ljudmi |
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 9 JCO2202604. Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson, Adam S Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N Tanaka, Terrence J Bradley, Deepa Jeyakumar, Eunice S Wang, Kendra Sweet, Hagop M Kantarjian, Guillermo Garcia-Manero, Rami Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F Zeidner, David A Sallm |
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, Noel Laudi, Mary W Redman, Jhanelle E Gray, David R Gandara, Karen Kel |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: